Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received ... Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...